WO2006131784A1 - Mousses pour cavites corporelles - Google Patents

Mousses pour cavites corporelles Download PDF

Info

Publication number
WO2006131784A1
WO2006131784A1 PCT/IB2005/004164 IB2005004164W WO2006131784A1 WO 2006131784 A1 WO2006131784 A1 WO 2006131784A1 IB 2005004164 W IB2005004164 W IB 2005004164W WO 2006131784 A1 WO2006131784 A1 WO 2006131784A1
Authority
WO
WIPO (PCT)
Prior art keywords
active agent
composition
foam
agent
foamable composition
Prior art date
Application number
PCT/IB2005/004164
Other languages
English (en)
Inventor
Dov Tamarkin
Doron Friedman
Meir Eini
Alex Besonov
Original Assignee
Foamix Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foamix Ltd. filed Critical Foamix Ltd.
Priority to EP05857859A priority Critical patent/EP1768648A1/fr
Priority to CA002565754A priority patent/CA2565754A1/fr
Priority to IL173092A priority patent/IL173092A/en
Publication of WO2006131784A1 publication Critical patent/WO2006131784A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Definitions

  • the invention relates to an alcohol-free, foam carrier for delivery of an active agent to a mucosal body cavity. More specifically, the invention relates to foam carriers suitable for inclusion of poorly soluble, water soluble and oil soluble therapeutic agents for delivery and sustained release to the vaginal cavity.
  • the vaginal cavity including the vagina and cervix, provides a unique site for delivery of therapeutic agents, both for systemic and local action.
  • the vagina consists of a tube of autonomically-innervated smooth muscle (longitudinal outer, inner circular layer) lined by stratified squamous epithelium and a sub-dermal layer rich in capillaries.
  • the vaginal wall consists of an inner glandular mucous type stratified squamous cell epithelium supported by a thick lamina propia. This epithelium undergoes hormone-related cyclical changes including slight keratinization of the superficial cells during the menstrual cycle. Deep in the epithelium lies the smooth muscles of the muscularis. There is a deeper surrounding fibrous layer above the muscularis which provides structural support to the vagina and is rich is collagen and elastin to allow for expansion of the.
  • Three sets of skeletal muscles surround the vagina including the ischiocavernosum, bulbocavernosus, transverse perinei and levator ani and pubococcygeus muscles.
  • Her who already have an infection are more likely to acquire or transmit another STD, including HIV.
  • Other biological risks include the use of vaginal douches, which increase the risk of pelvic inflammatory disease (PID), and the influence of hormonal contraceptives on acquiring or transmitting an STD (e.g., increased risk of chlamydial infection with use of oral contraceptives).
  • PID pelvic inflammatory disease
  • hormonal contraceptives e.g., increased risk of chlamydial infection with use of oral contraceptives.
  • the cervix is prone to several diseases, such as cervicitis (an inflammation of the uterine cervix, usually caused by infection), cancer, inflammation, erosion, intraepithelial neoplasia (CIN), polyps, dysplasia, human papillomavirus (HPV) infections causing some tumors, condylomas or warts and abnormal pregnancy.
  • cervicitis an inflammation of the uterine cervix, usually caused by infection
  • cancer inflammation, erosion, intraepithelial neoplasia (CIN), polyps, dysplasia, human papillomavirus (HPV) infections causing some tumors, condylomas or warts and abnormal pregnancy.
  • CIN intraepithelial neoplasia
  • HPV human papillomavirus
  • Vaginal topical formulation should be compatible with daily activities, be easy to administer and provide accurate dosing.
  • Several types of formulations are known for delivery to the vaginal cavity. While semi-solid formulations, such as creams, lotions, gels and ointments are commonly used, they are often reported to be messy, require frequent application and can be difficult to remove after use. Furthermore, application of topical gels and creams require several steps of operation. Solid formulations such as tablets, suppositories and pessaries also require frequent application, show a poor retention in vagina, and exhibit insufficient spreadability.
  • Rectal drug administration can be directed to both local and systemic drug delivery. It has been effectively used to treat local diseases of the anorectal area as well as an alternative to oral administration in the systemic administration of drugs.
  • Solid suppositories are the most common dosage form used for rectal drug administration and represent the majority of rectal dosage forms; however, creams ointments and foams are also being used.
  • Current formulations for rectal administration still have significant disadvantages. They are difficult to insert through the anal orifice; they are difficult to spread throughout the target cavity; and if spreadable, they tend to leak, causing major discomfort to the patient. Such negative attributes lead to their very limited use.
  • a product for intravaginal and anorectal application would ideally exhibit the following properties: (1) easy insertion, thus leading to high patient compliance; (2) accurate dosing, to ensure effective treatment; (3) expandability, for increased coverage of the target cavity surface and cervix; and (4) drip free formulation with good adhesive properties, for prolonged drug residence.
  • the duration of the drug inside the vagina or rectum is also important for ensuring extended activity.
  • Emulsion systems provide a two-phase system including water in one phase and oily components in the second phase.
  • Emulsifiers for reducing surface tension and for improving foam stability are included in the foam composition.
  • Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Slight shifts in foam emulsion composition, such as by the addition of active ingredients, may destabilize the foam.
  • high surfactant concentrations are required to attain foams of low density and acceptable texture.
  • Typical vaginal foam products are aqueous formulations and do not include significant levels of an oil-based solvent.
  • a nonoxynol-9-containing foam marketed under the trademane Delfen® foam (Advanced care, 12.5% nonoxynol-9), Emko® foam (Schering-Plough Healthcare, 12% nonoxynol-9) does not contain any oily solvent and has an ingredient list reciting "nonoxynol-9 12.5%, benzoic acid, cetyl alcohol, glacial acetic acid, methylparaben, perfume, phosphoric acid, polyvinyl alcohol, propellant a-31, propylene glycol, purified water, sodium carboxymethylcellulose, sorbic acid, stearamidoethyl diethylamine, stearic acid".
  • PCT Publication No. WO 03/053292 discloses drug delivery compositions, which are suitable for vaginal administration for the treatment of diseases and disorders in the urogenital tract.
  • the compositions may be in the form of a tablet, liquid suspension or dispersion; dried powder; topical ointment; cream; foam; suppository; or aerosol.
  • the drug delivery compositions are administered directly to the vagina and do not require the use of a pressurized canister or other foaming device.
  • the reference does not disclose use of hydrophobic or oily solvents.
  • US Patent No. 5,759,520 discloses an aqueous foamable composition having a delayed foaming action on expulsion from a pressurized container.
  • the composition includes (a) a major amount by weight of water; (b) 0.5 to 7.0 weight percent of a foaming agent in the form of a water-immiscible liquefied gas; (c) at least one foam- stabilizing and emulsifying surfactant; and (d) a water-soluble polymer.
  • a foaming agent such as propellant gas forms a foam upon discharge from the container. Water is used as the foam vehicle and hydrophobic organic carriers such as oil or emollients are not disclosed.
  • PCT Publication No. WO 02/00820 discloses a propellant-free foamable aqueous composition for use as vaginal or hemorrhoidal wipe.
  • the aqueous stable foam includes water, at least one surfactant and at least one foam-stabilizing agent. Such compounds are storage stable and readily dispensed by a propellantless mechanical pump.
  • US Patent No. 5,679,324 pertains to an aerosol foamable fragrance composition, translucent in its pre-dispensed state, which forms a fast-breaking foam.
  • the composition contains a surfactant selected from the group consisting of ethoxylated lanolin oil derivatives, propoxylated lanolin oil derivatives, and mixtures thereof, a propellant, a fragrance, a thickener, and a cosmetic vehicle (preferably water) wherein the ratio of the surfactant to propellant is from about 1 :1 to about 1 :10.
  • a surfactant selected from the group consisting of ethoxylated lanolin oil derivatives, propoxylated lanolin oil derivatives, and mixtures thereof, a propellant, a fragrance, a thickener, and a cosmetic vehicle (preferably water) wherein the ratio of the surfactant to propellant is from about 1 :1 to about 1 :10.
  • Emollients may be included, however, being translucent, the composition cannot comprise significant oil concentrations (which would make it opaque). Apparently the foam breaks spontaneously upon discharging from an aerosol container (with no need of any rubbing or sheer force application), thus making it impractical for intravagina
  • 5,536,743 and 5,840,744 relate to a non-flowing composition and method for intravaginal treatment of bacterial vaginosis.
  • the composition contains metronidazole with a buffer system providing an acidic buffered pH value in the range of 3.75 to about 4.25.
  • Certain of the compositions disclosed are based on mineral oil or petrolatum.
  • the foam compositions disclosed include up to 3% mineral oil as the hydrophobic component of the emulsion.
  • US Patent No. 6,544,530 provides a stable oil-in-glycerin composition comprising a continuous glycerin phase, at least one vegetable oil, at least one biodegradable emulsifier and at least one bioactive essential oil component for topical, external use on skin and mucosal.
  • the essential oil is a volatile mixture of esters, aldehydes, alcohols, ketones, and terpenes that possess bioactivity such as topical antifungal activity, topical anti-bacterial activity, topical anti-parasitic activity, and topical antiviral activity.
  • US Patent No. 5,993,846 discloses a method for making an oil-in-water emulsion having mucoadhesive properties which includes forming a mixture of a mucoadhesive macromolecule and an aqueous phase; emulsifying the mixture with a hydrophobic phase and a surfactant to form an oil-in-water emulsion comprising a plurality of submicron particles having a hydrophobic core surrounded by the surfactant and the mucoadhesive macromolecule; and providing the emulsion with a final pH of between 3 and 8.
  • US Patent No. 6,423,323 describes an aqueous foam emulsion.
  • the composition includes a hydrophobic phase including fatty acids, emulsifiers and co- emulsifiers, and an aqueous phase containing hydrophilic moisturizers and emulsifiers.
  • An optional ingredient is one or more refatting substances.
  • US Pat. No. 6,730,288 teaches a pharmaceutical foam composition including (a) an active ingredient; (b) an occlusive agent; (c) an aqueous solvent; and (d) an organic cosolvent; wherein the active ingredient is insoluble in water and insoluble in both water and the occlusive agent; and wherein there is enough occlusive agent to form an occlusive layer on the skin.
  • the present invention provides an easy to use vaginal delivery system that will be simple to operate with minimal preparation, will be very tolerable without having a feeling of foreign matter, will provide accurate dose administration, will evenly spread throughout the vaginal cavity surface, will effectively reach the cervix, will not leak and will retain intravaginally an active agent for a significant period of time.
  • the present invention provides a lubricating vaginal drug vehicle for moisture replenishing or moisturizing vaginal vehicles.
  • the invention provides an improved delivery system for active agents to other body cavities, such as the rectum, penile urethra, nasal cavity and ear cavity and to mucosal surfaces.
  • the present invention relates to foam compositions for intra-vaginal and body cavity application of a wide range of active ingredients.
  • the compositions contain at least one active agent in a biocompatible alcohol-free foamable carrier, including oleaginous foams, oil-in-water foams, water-in-oil foams, liposome-based foams and nanoparticle-based foams. These compositions provide long lasting, drip-free, expandable formulations for drug delivery into body cavities.
  • an alcohol-free foamable therapeutic composition for application to a body cavity or a mucosal surface includes: at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof hydrophobic organic carrier and mixtures thereof, at a concentration of about 2% to about 75% by weight; about 0.2% to about 5% by weight at least one surface-active agent; about 0.01% to about 5% by weight at least one polymeric agent, selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; at least one active agent at a therapeutically effective concentration; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, which upon release from an aerosol container provides an expanded foam suitable for topical administration.
  • at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof hydrophobic organic carrier and mixtures thereof, at a concentration
  • the composition further includes a foam adjuvant at a concentration less than about 5% by weight. Water and optional ingredients added to complete the total mass to 100%.
  • concentration percent by weight, %w/w.
  • the solvent level varies and can be at a level of about 2 to about 5, about 5% to about 20% by weight, or at a concentration of about 20% to about 75% by weight.
  • an alcohol free oleaginous therapeutic foam composition for administration to a body cavity or mucosal surface includes: at least one organic carrier selected from a hydrophobic organic carrier, an emollient, a polar solvent, and mixtures thereof, at a concentration of about 70% to about 99% by weight; at least one surface-active agent at a concentration of about 0.2 to about 15%; at least one polymeric agent, selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent at a concentration of about 0.1% to about 5% by weight; at least one active agent at a therapeutically effective concentration; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, which upon release from an aerosol container provides an expanded foam suitable for topical administration.
  • at least one organic carrier selected from a hydrophobic organic carrier, an emollient, a polar solvent, and mixtures thereof, at a concentration of about 70% to about 99% by weight
  • oleaginous foam composition means a stable foam composition, or a composition capable of forming a stable foam composition that contains a high level of oil or emollient as the hydrophobic organic carrier.
  • the hydrophobic organic carrier is included in the oleaginous foam composition at levels at or above 70%, and up to about 99% by weight.
  • composition components selected from the group consisting of organic carrier, surface active agent, foam adjuvant or polymeric agent can also function as an active agent.
  • a method of making a foamable composition includes selecting at least one active agent; selecting a solvent that solubilizes the active agent substantially better than a hydrocarbon solvent such as mineral oil or petrolatum, for example, 5 fold better than mineral oil or petrolatum, or even 10-fold better than mineral oil or petrolatum; and adjusting the type and concentration of surfactant and gelling agent, to provide a foamable composition.
  • a method of treating a syndrome, disease or disorder of a body cavity or mucosal surface includes administering an alcohol-free foamable therapeutic composition.
  • the foamable composition can be an oleaginous foam, an oil-in-water foam, a water-in-oil foam, a liposome based foam and a nanoparticle based foam.
  • the syndrome, disorder or disease of the body cavity is a syndrome, disorder or disease of the vaginal cavity.
  • the disorder is a microbial disorder including bacterial vaginosis, candidiasis, candidal vaginitis and trichomonas vaginitis.
  • the microbial disorder is a sexually transmitted disease (STD) such as chlamydia, herpes simplex, human immunodeficiency virus (HIV).
  • STD sexually transmitted disease
  • HSV human immunodeficiency virus
  • the syndrome, disorder or disease of the vaginal cavity is related to hormonal or post-menopausal vaginal dryness.
  • the syndrome, disorder or disease is related to the cervix and includes malignant and benign tumors, dysplasias, human papillomavirus (HPV) or to the vulva and includes lichen sclerosus, vulvodynia and other pathologies.
  • HPV human papillomavirus
  • the present invention provides a foamable therapeutic compositions useful for delivery of an active agent to a mucosal body cavity.
  • the composition is dispensed as a foam providing a stable product that is pleasant and easy to use for high patient compliance.
  • the foamable therapeutic composition of the present invention is suitable for facile administration into the rectum, bladder, the cavity between the uterus and the fallopian tubes, the ovaries and other body areas, which may accept topically-applied products.
  • a foamable composition includes water in one phase and at least one solvent selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof in the second phase.
  • the compositions may be water-in-oil or oil-in-water emulsions.
  • the present invention has surprisingly identified a series of foam compositions, which, upon admixing with a liquefied gas propellant in an aerosol container, produce a stable foam composition that is suitable for topical and mucosal administration to body cavities, such as the vagina, rectum, penile, urethra, nasal cavity and ear cavity.
  • body cavities such as the vagina, rectum, penile, urethra, nasal cavity and ear cavity.
  • the therapeutic foam composition for administration to a body cavity or mucosal surface includes at least one solvent selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a level of about 2% to about 5%, or about 5% to about 10%; or about 10% to about 20%; or about 20% to about 75%; or about 70% to about 99% by weight.
  • the composition also contains about 0.2% to about 5% by weight of a surface-active agent; about 0.01 % to about 5% by weight of a polymeric additive selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; at least one active agent at a therapeutically effective concentration; and a liquefied gas propellant at a concentration of about 3% to about 25% by weight of the total composition, which upon release from an aerosol container provides an expanded foam suitable for topical administration.
  • the composition further comprises a foam adjuvant at a concentration less than about 5%.
  • the foam composition is formulated as, an emulsion and can be an oil-in-water emulsion or a water-in-oil emulsion.
  • the choice of the type of emulsion is made in light of the nature of the active agent, so that it is suitable for inclusion of either or both water-soluble and oil- soluble active agents.
  • the choice of the type of emulsion is also influenced by the type of interaction which is desirable between the composition, the active agent and the target tissue.
  • the emulsion is a micro-emulsion.
  • Microemulsions are dispersions of either oil-in-water or water-in-oil, which are typically clear, as the droplet diameter is approximately 100 nanometers (nm) or less.
  • the foam composition of the present invention comprises liposomes.
  • the foam composition of the present invention comprises nanoparticles, and, for example, the diameter is about 200 nm to about 400 nm. Nanoparticles are typically introduced as an active agent.
  • the foam composition may include a propellant substance in an amount of about 3% to about 25% by weight, housed in an aerosol container.
  • the composition When released, the composition produces a foam, suitable for facile administration into body orifices and mucosal cavities, including, but not limited to the the vagina, the rectum and penile cavities, the urinary tract, bladder, the cavity between the uterus and the fallopian tubes, the ovaries and other body areas, which may accept topically-applied products .
  • the propellant helps provide a stable emulsion.
  • the propellant makes up part of the "oil phase" component of the emulsion, providing a product with long shelf-life.
  • admixing the liquid and solid foam components with a short chain hydrocarbon propellant results in a stable emulsion, that does not undergo phase separation after stress test, including either exposure to at least two freeze and though cycles.
  • a therapeutic product in one or more embodiments of the present invention, includes an active agent in a therapeutically effective concentration. Active agents are included in each of the compositions described herein; however, in some instances the solvent, which is part of the composition, provides therapeutic benefit and thus, can be defined as the at least one active agent. Therapeutic products are intended for topical treatment of human and animal disorders of body cavities, or any other disorder, that requires topical application of a drug into a body cavity.
  • the foamable composition of the present invention can be an emulsion, or microemulsion, including an aqueous phase and an organic carrier phase.
  • the organic carrier is selected from a hydrophobic organic carrier (also termed herein "hydrophobic solvent”), an emollient, a polar solvent, and a mixture thereof.
  • a “hydrophobic organic carrier” as used herein refers to a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL. It is liquid at ambient temperature.
  • the identification of a hydrophobic organic carrier or “hydrophobic solvent”, as used herein, is not intended to characterize the solubilization capabilities of the solvent for any specific active agent or any other component of the foamable composition.
  • the hydrophobic organic carrier is an oil, such as mineral oil.
  • Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that derive from petroleum. It is typically liquid; its viscosity is in the range of between about 35 CST and about 100 CST (at 4O 0 C), and its pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming so preventing flow) is below 0 0 C.
  • Term hydrophobic organic carrier does not include thick or semi-solid materials, such as white petrolatum, also termed "Vaseline", which, in certain compositions is disadvantageous due to its waxy nature and semi-solid texture.
  • hydrophobic solvents are liquid oils originating from vegetable, marine or animal sources.
  • Suitable liquid oil includes saturated, unsaturated or polyunsaturated oils.
  • the unsaturated oil may be olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod- liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils or mixtures thereof, in any proportion.
  • Suitable hydrophobic solvents also include polyunsaturated oils containing poly-unsaturated fatty acids.
  • the unsaturated fatty acids are selected from the group of omega-3 and omega-6 fatty acids.
  • examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
  • GLA gamma-linoleic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the hydrophobic solvent can include at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
  • oils that possess therapeutically-beneficial properties are termed "therapeutically active oil”.
  • Another class of hydrophobic solvents is the essential oils, which are also considered therapeutically active oil, which contain active biologically occurring molecules and, upon topical application, exert a therapeutic effect, which is conceivably synergistic to the beneficial effect of the steroid in the composition.
  • silicone oils also may be used and are desirable due to their known skin protective and occlusive properties. Suitable silicone oils include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)- (diphenyl-siloxane) copolymers.
  • non-volatile silicones such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)- (diphenyl-siloxane) copolymers.
  • cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms.
  • Volatile silicones such as cyclomethicones can also be used. Silicone oils are also considered therapeutically active oil, due to their barrier retaining and protective properties.
  • the hydrophobic carrier includes at least 2% by weight silicone oil or at least 5% by weight.
  • the solvent may be a mixture of two or more of the above hydrophobic solvents in any proportion.
  • a further class of solvents includes "emollients" that have a softening or soothing effect, especially when applied to body areas, such as the skin and mucosal surfaces.
  • Emollients are not necessarily hydrophobic.
  • suitable emollients include hexyleneglycol, propylene glycol, isostearic acid derivatives, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene
  • the hydrophobic organic carrier includes a mixture of a hydrophobic solvent and an emollient.
  • the foamable composition is a mixture of mineral oil and an emollient in a ratio between 2:8 and 8:2 on a weight basis.
  • a "polar solvent” is an organic solvent, typically soluble in both water and oil.
  • polar solvents include polyols, such as glycerol (glycerin), propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri- terpenes, terpen-ols, limonene, terpene-ol, 1 -menthol, dioxolane, ethylene glycol, other glycols, sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1 ,3- dioxolane
  • the polar solvent is a polyethylene glycol (PEG) or PEG derivative that is liquid at ambient temperature, including PEG200 (MW (molecular weight) about 190-210 kD), PEG300 (MW about 285-315 kD), PEG400 (MW about 380-420 kD), PEG600 (MW about 570-630 kD) and higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
  • PEG200 MW (molecular weight) about 190-210 kD
  • PEG300 MW about 285-315 kD
  • PEG400 MW about 380-420 kD
  • PEG600 MW about 570-630 kD
  • higher MW PEGs such as PEG 4000, PEG 6000 and PEG 10000 and mixtures thereof.
  • the solvent is a mixture (emulsion) of a hydrophobic organic carrier and glycerin, as described, for example, in US Pat.
  • the ratio of hydrophobic organic carrier to glycerin can range from about
  • a given solvent can be defined as both emollient and polar solvent.
  • hydrophobic organic carriers possess high solubilization capacity for pharmaceutical active agents, and are identified herein as
  • potent solvents are one that solubilizes a specific active agent substantially better than mineral oil or petrolatum, preferably 5 fold better than mineral oil or petrolatum, and even 10-fold better than mineral oil or petrolatum, and even 100-fold better than mineral oil or petrolatum.
  • a foam composition includes at least one active agent in a therapeutically effective concentration and a potent solvent.
  • the composition includes at least one active agent in a therapeutically effective concentration and at least one potent solvent in a sufficient amount to substantially solubilize the active agent in the composition.
  • substantially soluble means that at least 95% of the active agent has been solubilized, i.e., less than about 5% is present in the composition in a solid state.
  • the potent solvent is more than about 40% or more than about 60% by weight of the total solvent of the composition.
  • Betamethasone valerate Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1 % (w/w) in Glycofurol.
  • Hydrocortisone butyrate Practically insoluble in mineral oil ( ⁇ 0.01 %); soluble more than 1 % in Glycofurol.
  • Metronidazole Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1% in dimethyl isosorbide.
  • Ketoconazole Practically insoluble in mineral oil ( ⁇ 0.01%); soluble more than 1 % in glycofurol, propylene glycol and dimethyl isosorbide.
  • Mupirocin Practically insoluble in mineral oil ( ⁇ 0.01 %); soluble more than 1% in glycofurol, hexylene glycol, dimethyl isosorbide, propylene glycol and polyethylene glycol 400 (PEG 400).
  • Meloxicam a nonsteroidal anti-inflammatory agent: Practically insoluble in mineral oil ( ⁇ 0.001%); soluble in propylene glycol: 0.3 mg/mL and in PEG 400: 3.7 mg/mL.
  • Progesterone Practically insoluble in mineral oil ( ⁇ 0.001%); soluble in PEG 400:
  • a non-limiting exemplary list of solvents that can be considered as potent solvents includes polyethylene glycol, propylene glycol, hexylene glycol, butanediols and isomers thereof, glycerol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol).
  • the present invention also provides a method of designing a foamable composition by selecting at least one active agent, selecting a solvent that solubilizes the active agent substantially better than mineral oil or petrolatum, and adjusting the type and concentration of surfactant and gelling agent to provide a foamable composition. This is particularly useful in fomulating foams incorporating poorly soluble active agents.
  • the use of a potent solvent in a foam composition provides an improved way to deliver poorly soluble active agents to a target area. It is known that low drug solubility results in poor bioavailability, leading to decreased effectiveness of treatment.
  • Foam compositions according to one or more embodiments of the present invention for which the solvent is a potent solvent are unique because the majority of the active agent is in solution, rather than in particulate form, resulting in high delivery and improved therapy.
  • Potent solvents are typically in liquid form.
  • Liquid drug formulations are generally disadvantageous, since their usage causes unwanted dripping, resulting in inconvenience and inadequate dosing.
  • the foams of the present invention are drip-free and thereby provide a superior vehicle for such drugs and enable convenient usage and accurate effective dosing.
  • Surface-active agents include any agent linking oil and water in the composition in the form of emulsion.
  • a surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil.
  • the HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
  • Lipophilic emulsifiers form water-in-oil (w/o) emulsions
  • hydrophilic surfactants form oil-in-water (o/w) emulsions.
  • the HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
  • the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an O/W emulsion of a given oil) of most oils and hydrophobic organic carriers.
  • HLB hydrophilic lipophilic balance
  • the composition is a single surface active agent having an HLB value between about 9 and 14, and in one or more embodiments, the composition is more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14.
  • the surface-active agent in an oleaginous composition has a surface- active agent with an HLB in the range of about 3 to about 9.
  • the surface-active agent is selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the therapeutic and cosmetic formulation art.
  • Nonlimiting examples of possible surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and poly(oxyethylene) (20) sorbitan monooleate (Tween 80); poly(oxyethylene) (POE) fatty acid esters, such as Myrj 45, Myrj 49, Myrj 52 and Myrj 59; poly(oxyethylene) alkylyl ethers, such as poly(oxyethylene) cetyl ether, poly(oxyethylene) palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1; sucrose esters, partial esters of sorbitol and its anhydrides, such as sorbitan monolaurate and sorbitan monolaurate; mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lau
  • the surface-active agent includes at least a non-ionic surfactant.
  • Ionic surfactants are known to be irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive tissue such as found in most mucosal tissues, especially when they are infected or inflamed. We have surprisingly found that non-ionic surfactants alone provide foams of excellent quality, i.e. a score of "E" according to the grading scale discussed herein below.
  • the surface active agent includes a mixture of at least one non-ionic surfactant and at least one ionic surfactant in a ratio in the range of about 100:1 to 6:1. In one or more embodiments, the non-ionic to ionic surfactant ratio is greater than about 6:1 , or greater than about 8:1 ; or greater than about 14:1 , or greater than about 16:1 , or greater than about 20:1.
  • a combination of a non- ionic surfactant and an ionic surfactant is employed, at a ratio of between 1 :1 and 20:1 , or at a ratio of 4:1 to 10:1.
  • the resultant foam has a low specific gravity, e.g., less than 0.1g/ml.
  • the surface-active agent includes mono-, di- and tri-esters of sucrose with food fatty acids (sucrose esters), prepared from sucrose and esters of fatty acids or by extraction from sucro-glycerides. Suitable sucrose esters include those having high monoester content, which have higher HLB values.
  • the total surface active agent required to obtain a foam that is stable, of low specific gravity and has a fine bubble structure is low. This is desirable because lower surface active agent levels, particularly of ionic surfactants, reduce skin irritations.
  • Total surface active agent is in the range of about 0.1 to about 5% of the foamable composition, and is typically less than about 2%, preferably less than about 1 %.
  • stable foam denotes shelf life stability of the emulsion and also a sustainable foam that does not break upon extrusion of the package to enable delivery, spreading and expansion of the foam throughout the entire vaginal cavity before collapse.
  • the foamable composition includes a polymeric agent to increase the duration/residence time of the composition in the body cavity.
  • the polymeric agent serves to stabilize the foam composition and to control drug duration in the target organ.
  • Exemplary polymeric agents, which provide means of controlling duration are classified below in a non-limiting manner. In certain cases, a given polymer can belong to more than one of the classes provided below.
  • Bioadhesion has been defined as the attachment of synthetic or biological macromolecules to a biological tissue.
  • mucoadhesion refers to the special case of bioadhesion where the biological tissue is an epithelium covered by mucous, for example such as found in the vagina, gastrointestinal tract and the nasal cavity.
  • Mucoadhesive agents are a class of polymeric biomaterials that exhibit the basic characteristic of a hydrogel, i.e. swell by absorbing water and interacting by means of adhesion with the mucous that covers epithelia.
  • compositions of the present invention may contain a mucoadhesive macromolecule or polymer in an amount sufficient to confer bioadhesive properties.
  • the bioadhesive macromolecule enhances the delivery of biologically active agents on or through the target surface.
  • the mucoadhesive macromolecule may be selected from acidic synthetic polymers, preferably having at least one acidic group per four repeating or monomeric subunit moieties, such as poly(acrylic)- and/or poly(methacrylic) acid (e.g., Carbopol®, Carbomer®), poly(methylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC); neutral synthetically modified natural polymers, such as (hydroxypropyl)methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral synthetic polymers, such as polyvinyl alcohol or their mixtures.
  • acidic synthetic polymers preferably having at least one acidic group per four repeating or monomeric subunit moie
  • An additional group of mucoadhesive polymers includes natural and chemically modified cyclodextrin, especially hydroxypropyl- ⁇ -cyclodextrin (HP ⁇ CD).
  • Such polymers may be present as free acids, bases, or salts, usually in a final concentration of about 0.01 % to about 0.5% by weight.
  • a suitable bioadhesive macromolecule is the family of acrylic acid polymers and copolymers, (e.g., Carbopol®). These polymers contain the general structure -[CH 2 - CH(COOH) ⁇ ] n . Hyaluronic acid and other biologically-derived polymers may be used.
  • Exemplary bioadhesive or mucoadhesive macromolecules have a molecular weight of at least 50 kDa, or at least 300 kDa, or at least 1 ,000 kDa.
  • polymeric ionizable macromolecules have not less than 2 mole percent acidic groups (e.g., COOH, SO 3 H) or basic groups (NH 2 , NRH, NR 2 ), relative to the number of monomeric units.
  • the acidic or basic groups can constitute at least 5 mole percent, or at least 10 mole percent, or at least 25, at least 50 more percent, or even up to 100 mole percent relative to the number of monomeric units of the macromolecule.
  • mucoadhesive agent includes inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSlL 200 (DEGUSSA).
  • inorganic gelling agents such as silicon dioxide (fumed silica), including but not limited to, AEROSlL 200 (DEGUSSA).
  • a gelling agent controls the residence of a therapeutic composition in the target site of treatment by increasing the viscosity of the composition, thereby limiting the rate of its clearance from the site.
  • Many gelling agents are known in the art to possess mucoadhesive properties.
  • the gelling agent can be a natural gelling agent, a synthetic gelling agent and an inorganic gelling agent.
  • Exemplary gelling agents that can be used in accordance with one or more embodiments of the present invention include, for example, naturally- occurring polymeric materials, such as locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g.
  • hydroxyethyl cellulose methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose
  • guar gum hydroxypropyl guar gum
  • soluble starch cationic celluloses, cationic guars, and the like
  • synthetic polymeric materials such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Mixtures of the above compounds are contemplated.
  • Further exemplary gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol® resins. These resins consist essentially of a colloidal water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Carbopol® 934, Carbopol® 940, Carbopol® 950, Carbopol® 980, Carbopol® 951 and Carbopol® 981.
  • Carbopol® 934 is a water- soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
  • another group of gelling agents includes inorganic gelling agents, such as silicone dioxide (fumed silica).
  • the foam composition contains at least one film forming component.
  • the film forming component may include at least one water-insoluble alkyl cellulose or hydroxyalkyl cellulose.
  • Exemplary alkyl cellulose or hydroxyalkyl cellulose polymers include ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, hydroxypropyl cellulose, hydroxybutyl cellulose, and ethylhydroxyethyl cellulose, alone or in combination.
  • a plasticizer or a cross linking agent may be used to modify the polymer's characteristics.
  • esters such as dibutyl or diethyl phthalate, amides such as diethyldiphenyl urea, vegetable oils, fatty acids and alcohols such as oleic and myristyl acid may be used in combination with the cellulose derivative.
  • the composition of the present invention includes a phase change polymer, which alters the composition behavior from fluid-like prior to administration to solid-like upon contact with the target mucosal surface.
  • phase change results from external stimuli, such as changes in temperature or pH and exposure to specific ions (e.g., Ca++).
  • phase change polymers include poly(N- isopropylamide), Poloxamer 407® and Smart-Gel® (Poloxamer + PAA).
  • the polymeric agent is present in an amount in the range of about 0.01% to about 5.0% by weight of the foam composition. In one or more embodiments, it is typically less than about 1 wt% of the foamable composition.
  • a foam adjuvant is optionally included in the foamable compositions of the present invention to increase the foaming capacity of surfactants and/or to stabilize the foam.
  • the foam adjuvant agent includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof).
  • fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1 -triacontanol (C30), as well as alcohols with longer carbon chains (up to C50).
  • Fatty alcohols, derived from beeswax and including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents.
  • the amount of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains.
  • the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
  • fatty acids having 16 or more carbons in their carbon chain
  • the amount of fatty acids required to support the foam system is inversely related to the length of its carbon chain.
  • the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond.
  • a further class of foam adjuvant agent includes a branched fatty alcohol or fatty acid.
  • the carbon chain of the fatty acid or fatty alcohol also can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
  • the foam adjuvant according to one or more embodiments of the present invention includes a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass. More preferably, the total amount is 0.4% - 2.5% (w/w) of the carrier mass.
  • fatty alcohols and fatty acids serve to stabilize the resultant foam composition, they often provide additional therapeutic properties.
  • Long chain saturated and mono unsaturated fatty alcohols e.g., stearyl alcohol, erycyl alcohol, arachidyl alcohol and docosanol have been reported to possess antiviral, anti infective, antiproliferative and anti-inflammatory properties (US Patent No. 4,874,794).
  • Longer chain fatty alcohols e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc. are also known for their metabolism modifying properties and tissue energizing properties.
  • Long chain fatty acids have also been reported to possess anti-infective characteristics.
  • the therapeutic or cosmetic carrier, containing the foam adjuvant agent of the present invention provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
  • Lower alcohols having up to 5 carbon atoms in their carbon chain skeleton such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol, are considered less desirable solvents or polar solvents due to their skin-irritating effect.
  • composition is substantially alcohol-free and should comprise less than about
  • the therapeutic foam of the present invention may further optionally include a variety of formulation excipients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and modify their consistency.
  • formulation excipients may be selected, for example, from stabilizing agents, antioxidants, humectants, preservatives, colorant and odorant agents and other formulation components, used in the art of formulation.
  • Aerosol propellants are used to generate and administer the foamable composition as a foam.
  • the total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable carrier.
  • the propellant makes up about 3% to about 25 wt% of the foamable carrier.
  • suitable propellants include volatile hydrocarbons such as butane, propane, isobutane or mixtures thereof, and fluorocarbon gases.
  • compositions described herein including water, additional solvents, formulation excipients, active agents and propellant creates a stable emulsion that does not exhibit full phase separation at ambient temperature for at least a year.
  • compositions including semi-solid hydrophobic organic carriers e.g., white petrolatum, are excessively viscous and demonstrate poor flowability.
  • the combination of at least one surface active agent, at least one polymeric agent and optionally at least one foaming adjuvant, according to one or more embodiments of the invention provides a low specific gravity foam having superior expandability, flow properties and sheer breakability (among other attributes).
  • the total amount of at least one surface active agent, at least one polymeric agent and optionally at least one foaming adjuvant, in combination does not exceed 8 % (w/w) of foamable composition.
  • the combined amounts of at least one surface active agent, at least one polymeric agent and optionally at least one foaming adjuvant is less than 5 % (w/w) of foam composition.
  • the low solid content improves the flow properties of the foam, reduces unpleasant skin residue and reduces the cost of manufacture. As is demonstrated herein, the foam stability and expandability are excellent, despite the low levels of these components in the foam.
  • Expandability is an important feature of a product that is intended to treat internal cavities of the body.
  • the specific gravity of the foam, upon discharge from the foam dispenser is between about 0.02 gr/mL and 0.4 gr/mL, or between about 0.04 gr/mL and about 0.14 gr/mL.
  • the following scale for foam quality is used to evaluate foams.
  • E excellent: very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure.
  • VP very poor: dry foam, large very dull bubbles, difficult to spread on the skin.
  • Foams that are adequate for topical administration according to the present invention have to be of quality grade E or G, upon release from the foam dispenser. Smaller bubbles mean more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
  • the foam compositions are stable for a prolonged period of time.
  • the foam composition does not undergo phase separation following at least two freeze and thaw cycles.
  • a foam dispenser e.g., an aerosol can
  • the foam Upon discharge from a foam dispenser, e.g., an aerosol can, onto a mucosal membrane at about 37°C, the foam expands to reach its designated volume and stays stable as a foam for at least 60 seconds, or 2 minutes, or even 3 minutes, following application. Metered dosing
  • the foam therapeutic product is adapted for storage in a foam dispenser having a metered dose valve for dispensing an accurate dose of drug in the form of a foam.
  • the metered dose valve is selected to release a foam in a volume that is in the size of the target body cavity to allow effective spreading of the active agent throughout the body cavity with substantially minimal overflow.
  • the meter dose valve provides a unit dose of between about 10 ⁇ l_ and about 1000 ⁇ L.
  • vaginal and rectal dosage form relates to the dimensions of the product applicator.
  • an insert applicator 10 cm long and about 1.5 cm thick is employed. It is to be understood that such a thick applicator is found repulsive by patients, which leads to poor patient compliance. Furthermore, the length of the applicator, which is beyond the natural depth of a relaxed vaginal cavity, makes it difficult for the patient to accurately administer the composition into the target organ.
  • a foam composition according to the present invention is not limited by applicator dimensions.
  • the insert is thin and thus, it is acceptable to the patient.
  • the thickness of the aerosol insert can range between about 0.2 cm and about 1 cm.
  • the aerosol insert can be designed in any length, to fit the dimensions of the target organ.
  • the length of a vaginal insert can range between about 2 cm and about 10 cm; the length of an insert for the nasal system or ear canal can be shorter and the insert for rectal administration can be adjusted according to the location of the disorder, between about 1 cm and about 20 cm.
  • the insert is designed to be flexible, to allow insertion into a body cavity that is difficult to access using a non-flexible insert.
  • an appropriate active agent in the foamable composition By including an appropriate active agent in the foamable composition, it is useful in the therapy and prevention of a variety of disorders of a body cavity or mucosal surfaces, including, but not limited to the cranial cavity, the thoracic cavity, the abdominal cavity, the ventral cavity, the vagina, the rectum and penile cavities, the urinary tract, bladder, the cavity between the uterus and the fallopian tubes, the ovaries, the nasal cavity, the mouth, the eye, the ear the peritoneum, the large and small bowel, the caecum, bladder, and stomach, and other body cavities or spaces, which may accept topically-applied products.
  • Exemplary treatable disorders are listed below.
  • Bacterial, fungal and viral infections a variety of anti-infective, anti-bacterial, anti-fungal and anti-viral agents can be included in the foam of the present invention, to be used for the treatment and / or prevention of diseases, such as chlamydia, gonorrhea, hepatitis B, herpes, HIV/AIDS, human papallomavirus (HPV) & genital warts; syphilis; bacterial vaginosis, candidiasis, chancroid, granuloma inguinale, lymphogranloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, and vulvar disorders.
  • diseases such as chlamydia, gonorrhea, hepatitis B, herpes, HIV/AIDS, human papallomavirus (HPV)
  • a variety of active agents can be included in the foam to be used for the treatment and / or prevention of diseases such as vulvodynia (vulvar pain), yeast infections, genital warts (condyloma) vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), invasive cancer of the vulva, contact dermatitis, pelvic inflammation, pelvic inflammatory disease (PID), genital cancer and cancer of the cervix, vulva or vagina.
  • diseases such as vulvodynia (vulvar pain), yeast infections, genital warts (condyloma) vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), invasive cancer of the vulva, contact dermatitis, pelvic inflammation, pelvic inflammatory disease (PID), genital cancer and cancer of the cervix, vulva or vagina.
  • Vaginal dryness is caused by a number of conditions and can be either an occasional hassle or a chronic problem.
  • a variety of anti-inflammatory active agents, hormones, moisturizing, refatting and lubricating agents and local anesthetic agents can be included in the foam of the present invention, to be used for the treatment and / or prevention of vaginal dryness. Dvspareunia
  • Dysareunia is pain in the vagina or pelvis experienced during sexual intercourse.
  • a variety of anti-inflammatory active agents, hormones, moisturizing, refatting and lubricating agents and local anesthetic agents can be included in the foam of the present invention, to be used for the treatment and / or prevention of vaginal pain.
  • Anal and rectal disease such as anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease , hemorrhoids, anal itch, also called pruritus ani, fecal incontinence, and polyps of the colon and rectum all may be treated using the foamable composition according to one or more embodiments of the invention.
  • the foam composition of the present invention comprising an active agent that is known to treat one of said anorectal disorders and administered rectally, expands effectively in the rectal cavity and provides optimal coverage of the cavity surface, for improved therapeutic results.
  • the foam When comprising appropriate protective agents, the foam is active against HIV infection and other infections (bacterial and fungal), including sexually transmitted disease (STD) by creating a protective layer and/or decreasing the frequency of transmission.
  • protective agents include: [0128] Negatively charged sulfated polymers, which have been reported to have anti-HIV-1 activity and are being considered for development as topical microbicides. [0129] Dextrin sulphate, a microbicide, which in various laboratory and pre-clinical studies, has been shown to block the transfer of HIV virus into mammalian cells while at the same time not causing injury to normal cell tissue.
  • Cellulose acetate phthalate which inactivates HIV-1 , herpesvirus types 1 (HSV-1) and 2 (HSV-2) and the major nonviral STD pathogens; and found effective in animal models for vaginal infection by HSV-2 and simian immunodeficiency virus.
  • HSV-1 herpesvirus types 1
  • HSV-2 herpesvirus types 1
  • HSV-2 herpesvirus types 2
  • simian immunodeficiency virus Several polymers, such as hydroxypropyl methylcellulose phthalate, carrageenans, naphthalene sulfonate polymer, sodium alginate, and cationic polymer, such as chitosan, are insoluble in water and can be solubilized in water by adjusting the pH of the environment to about 6 or above, or by the use of appropriate organic solvents.
  • Vaginal secretions from healthy, reproductive-age women are characteristically acidic (pH values of 3.4 to 6.0). Consequently, the topical application of a formulation in which such polymers would be soluble (i.e., pH ⁇ 6) would be expected to contribute to a vaginal environment which is physiologically undesirable.
  • an oily foamable carrier comprising solvents that solubilize water-insoluble polymenrs such as mentioned above.
  • such solvents include polyethylene glycol, propylene glycol, hexylene glycol, benzyl alcohol, DMSO, isosorbide derivatives, such as dimethyl isosorbide, glycofurol and ethoxydiglycol (transcutol).
  • the foam composition is useful in the therapy of disorders that respond to transmucosal delivery of an active agent.
  • disorders include, which respond to hormone therapy, such as hormone replacement therapy, and other systemic disorders, known to be affected by drugs that are delivered transmucosally.
  • a mucosal vaccine The goal of a mucosal vaccine is to induce antigen-specific immune responses (cellular and humoral) that are detectable at the mucosal surfaces of the host. Because many pathogens initiate infection at the mucosal surfaces, pathogen-specific mucosal immune responses may provide superior protection against infectious diseases than immune responses induced by parenteral vaccines because parenteral vaccines do not induce mucosal immunity.
  • the term immunization or vaccination refers to administering a preparation that contains an infectious agent or its components, which is able to stimulate an immune response that will protect a person from illness due to that agent.
  • Such vaccines are expected be capable of preventing the transmission or limiting the severity of sexually-transmitted infections, such as HIV and other infectious disease.
  • Vaccines are usually administered in conjunction with an adjuvant- a substance that is used in a vaccine to improve the immune response so that less vaccine is needed to produce a non-specific stimulator of the immune response.
  • adjuvants including, for example, minerals such as aluminum hydroxide, aluminum phosphate and calcium phosphate, oil emulsions, products from bacteria (their synthetic derivatives as well as liposomes) or gram-negative bacteria, endotoxins, cholesterol, fatty acids, aliphatic amines, paraffinic and vegetable oils.
  • the foam composition of the present invention comprising an immunizing agent, and optionally an adjuvant and administered onto the mucosal tissue of a body cavity, expands effectively in said cavity and provides optimal coverage of the cavity surface, for improved therapeutic results.
  • Post-surgical adhesions treatment and prevention comprising an immunizing agent, and optionally an adjuvant and administered onto the mucosal tissue of a body cavity, expands effectively in said cavity and provides optimal coverage of the cavity surface, for improved therapeutic results.
  • Adhesions are scars that form abnormal connections between tissue surfaces. Post-surgical adhesion formation is a natural consequence of surgery, resulting when tissue repairs itself following incision, cauterization, suturing, or other means of trauma.
  • the foam is suitable for the treatment or prevention of post surgical adhesions. The use of foam is particularly advantageous because foam can expand in the body cavity and penetrate into hidden areas that cannot be reached by any other alternative means of administration.
  • the foamable composition of the present invention is suitable for administering a hormone to a mucosal membrane or a body cavity, in order to deliver the hormone into the tissue of the target organ, in any disorder that responds to treatment with a hormone.
  • Topically applied hormones can also be useful in contraception, when administered in foam, using a metered dose unit.
  • the composition of the present invention comprises at least one active agent, also referred to as "drug(s)".
  • the at least one active agent may consist of a single drug or a combination of drugs that can be dissolved in the water phase or the hydrophobic phase of the carrier composition.
  • examples of such drugs are antibiotic, antibacterial, antifungal, antiviral, antiinflammatory, anesthetic, analgesic, antiallergic, corticosteroid and antiproliferative medications and mixtures thereof at any proportion.
  • the concentration of drugs may be adopted to exert a therapeutic effect on a disease when applied to an afflicted area.
  • One important class of drugs comprises antibacterial agents. It is well known that bacterial infections are involved in a variety of superficial disorders of mucosal membranes and body cavities.
  • the antibiotic agent is selected from the classes consisting of beta-lactam antibiotics, aminoglycosides, ansa-type antibiotics, anthraquinones, azoles, glycopeptides, macrolides, nucleosides, antibiotic peptides, antibiotic polyenes, antibiotic polyethers, quinolones, antibiotic steroids, sulfonamides, tetracycline, antibiotic metals, including silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium and ions and complexes thereof, oxidizing agents and substances that release free radicals and/or active oxygen, cationic antimicrobial agents,quaternary ammonium compounds, biguanides, triguanides, bisbiguanides and analogs and polymers thereof and naturally occurring antibiotic compounds.
  • an antibacterial drug can be active against gram positive and gram-negative bacteria, protozoa, aerobic bacteria and anaerobic bacteria.
  • the antibacterial drugs are selected from chloramphenicol, beta-lactam antibiotics, aminoglycosides, ansa-type antibiotics, anthraquinones, azoles, glycopeptides, macrolides, nucleosides, antibiotic peptides, antibiotic polyenes, antibiotic polyethers, quinolones, antibiotic steroids, sulfonamides, tetracycline, antibiotic metals, including silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium and ions and complexes thereof, oxidizing agents and substances that release free radicals and/or active oxygen, cationic antimicrobial agents,quatemary ammonium compounds, biguanides, triguanides, bisbiguanides and analogs and polymers thereof and naturally occurring antibiotic compounds, metronida
  • Another group of antibacterial agents which have broad spectrum activity comprises strong oxidants and free radical liberating compounds, such as oxygen, hydrogen peroxide, benzoyl peroxide, elemental halogen species, as well as oxygenated halogen species, bleaching agents (e.g., sodium, calcium or magnesium hypochloride and the like), perchlorite species, iodine, iodate, and benzoyl peroxide.
  • Organic oxidizing agents are also included in the definition of "oxidizing agent” according to the present invention, such as quinones. Such agents possess a potent broad spectrum activity.
  • Antibacterial compositions according to the present invention are selected to treat infections of an afflicted organ.
  • composition of the present invention comprising a hydrophobic component, would facilitate an enhanced rate of penetration. Furthermore, the intrinsic antibacterial and antiinflammatory effects of the foam adjuvant agents, i.e., fatty alcohols and acids, provides a combined effect for better therapeutic response to treatment.
  • foam adjuvant agents i.e., fatty alcohols and acids
  • Fungal infections are another object of treatment using the composition of the present invention.
  • Fungal infection of the vaginal cavity is one of the most common disorders seen in gynecological practice.
  • Candidiasis is an infection caused by the yeast like fungus Candida albicans or occasionally other species of Candida.
  • Clinical syndromes of candidiasis include: (a) oral candidiasis (oral thrush); (b) candidiasis of the skin and genital mucous membrane; and (c) Candida paronychia, which inflicts the nail.
  • the therapeutic composition may comprise an antifungal drug, which is active against dermatophytes and Candida, selected from the group of, but not limited to azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, potassium iodide, flucytosine (5FC) and any combination thereof at a therapeutically effective concentration.
  • the active agent is metronidazole.
  • composition of the present invention is particularly beneficial in the case of viral infections including herpes simplex Type 1 virus.
  • Mollusca are small viral growths that appear singly or in groups on the face, trunk, lower abdomen, pelvis, inner thighs, or penis. Warts are a common, benign skin tumor caused by viral infection.
  • HPV Human Papillomavirus
  • Viral infections are currently treated with various antiviral agents, as summarized in the following table:
  • any of the above antiviral agents in a therapeutically effective concentration, can be incorporated in the foam composition of the present invention.
  • the composition of the present invention which comprises a hydrophobic organic carrier, would facilitate an enhanced rate of penetration and better topical distribution of any of the above listed antiviral drugs.
  • the intrinsic antiviral effects of the foam adjuvant agents i.e., fatty alcohols and acids, provides a combined effect that should result in a better therapeutic response to treatment.
  • the active agent is a steroid, selected from the following groups. a compound containing a cyclopenta[a]phenanthrene skeleton; a compound, containing a cyclopenta[a]phenanthrene skeleton carrying one or more functional groups selected from halogens, alkyl groups, aryl groups, benzyl groups, carboxy groups and alkoxy groups;
  • a steroid compound selected from the families of (a) cardanolides, (b) bufanolides, (c) spirostans, (d) furostans, (e) steroid alkaloids, (f) a steroid lactone, (g) an oxo-steroid, (h) a steroid-alcohol and (i) a steroid-amine; v. a steroid compound, where one or more of the cyclopenta[a]phenanthrene rings is contracted by loss of an unsubstituted methylene group; vi.
  • a steroid compound where one or more of the cyclopenta[a]phenanthrene rings is expandeded by inclusion of a methylene group; vii. a compound, containing a cyclopenta[a]phenanthrene skeleton and a carbocyclic or heterocyclic ring component fused to it; viii. an anti-inflammatory steroid; ix. a steroid possessing immunomodulating and/or anti-inflammatory properties; x. a steroid, selected from the group of low-potency anti-inflammatory steroids, medium potency anti-inflammatory steroids and high potency anti-inflammatory steroids; xi.
  • an anti-inflammatory steroid selected from the group consisting of hydrocortisone, hydrocortisone acetate, desonide, betamethasone valerate, clobetasone-17-butyrate, flucinonide, fluocinolone acetonide, alcometasone dipropionate, mometasone furoate, prednicarbate, triamcinolone acetonide, betamethasone-17-benzoate, methylprednisolone aceponate, betamethasone dipropionate, halcinonide, triamcinolone acetonide, halobetasol, clobetasol-17- propionate; xii.
  • a steroid hormone selected from the group consisting of an androgen, an estrogen and a progestogen xiv. an androgen, selected from the group consisting of testosterone, testosterone cipionate, testosterone decanoate, testosterone enantate, testosterone isocaproate, testosterone phenylpropionate, testosterone propionate, testosterone undecylate, 5 ⁇ -dihydrotestosterone, dehydroepiandrosterone (also termed prasterone and DHEA), androstenedione, androstanediol, androsterone, androstenolone, prasterone enantate, prasterone sodium sulfate, ormeloxifene, mesterolone, fluoxymesterone, methyltestosterone, gestrinone, delmadinone, delmadinone acetate, chlormadinone, chlormadinone acetate, danazol and testolactone
  • an estrogen selected from the group consisting of estradiol, estradiol benzoate, estradiol cipionate, estradiol dipropionate, estradiol enantate, estradiol hexahydrobenzoate, estradiol phenylpropionate, estradiol valerate, polyestradiol phosphate, estriol, estriol sodium succinate, estriol succinate, polyestriol phosphate, quinestradol, ethinylestradiol, estrapronicate, mestranol, estrapronicate and equilin; xvi.
  • a progestogen selected from the group consisting of progesterone, norethisterone, norethisterone acetate, norethisterone enantate, medroxyprogesterone acetate, delmadinone acetate, flugestone acetate, dydrogesterone, desogestrel, norgestrel, levonorgestrel, dydrogesterone, gestodene, chlormadinone acetate, dienogest, drospirenone, lynestrenol, tybolone, cyproterone acetate, megestrol acetate, nomegestrol acetate; xvii.
  • an inhibitor of a steroid hormone xviii. an inhibitor of a steroid hormone, selected from the group consisting of inhibitors are finasteride, dutasteride and spironolactone; xix. a vitamin D; xx.
  • a vitamin D selected from the group consisting of cholecalciferol, 25- hydroxycholecalciferol, 1 ⁇ ,25-dihydroxycholecalciferol, ergocalciferol, 1 ⁇ ,25- dihydroxyergocalciferol, 22,23-dihydroergocalciferol, 1 ,24,25- trihydroxycholecalciferol, previtamin D 3 , tachysterol 3 (also termed tacalciol), Isovitamin D 3 , dihydrotachysterol 3 , (1 S)-hydroxycalciol, (24fl)-hydroxycalcidiol, 25-fluorocalciol, ercalcidiol, ertacalciol, (5£)-lsocalciol, 22,23-Dihydroercalciol, (24S)-methylcalciol, (5E)-(1 OS)-10,19-Dihydroercalciol, (24S)-Eth
  • the at least one active agent is an antiinflammatory or antiallergic agent.
  • An antiinflammatory or antiallergic agent can be selected from the group of corticosteroids (as listed above), non-steroidal antiinflammatory drugs (NSAIDs), anti-histamines, immunosuppressants and any combination thereof at a therapeutically effective concentration.
  • corticosteroid drugs are typically hydrophobic
  • the carrier of the present invention comprising a hydrophobic organic carrier, is most suitable as a vehicle to facilitate better topical distribution and an enhanced rate of penetration of any of the above listed drugs.
  • Antihistaminic agents may comprise, among other options, diphenhydramine, doxepin, phrilamine maleate, chlorpheniramine, tripelennamine, phenothiazines, promethazine hydrochloride and dimethindene maleate. These drugs, as well as additional antihistamines can also be incorporated in the composition of the present invention.
  • a second class of anti-inflammatory agents which is useful in the foam of the present invention, includes the nonsteroidal anti-inflammatory agents (NSAIDs).
  • NSAIDs nonsteroidal anti-inflammatory agents
  • the variety of compounds encompassed by this group is well-known to those skilled in the art.
  • Specific non-steroidal anti-inflammatory agents useful in the composition invention include, but are not limited to: oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam; salicylates, such as salicylic acid, ethyl salicylate, methyl salycilate, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidome
  • the therapeutic foam composition of the present invention may also comprise an antiinflammatory or antiallergic agent, wherein said agent reduces the occurrence of pro-inflammatory cytokines or inhibits the effect of pro-inflammatory cytokines.
  • Mixtures of such anti-inflammatory agents may also be employed, as well as the dermatologically acceptable salts, esters, amides, prodrugs and derivatives of these agents.
  • compositions of the present invention may contain a safe and effective amount of a topical anesthetic.
  • topical anesthetic drugs include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, and ' therapeutically acceptable salts thereof.
  • Mixtures of such anesthetic agents may be synergistically beneficial.
  • Anti cancer agents can also be used according to the present invention as the drug of choice for treating for example vaginal, cervical and rectal malignancies.
  • topical cytotoxic and antiproliferative drugs are used to treat or prevent such cancers, including 5-fluorouracil, also called 5-FU.
  • 5-FU as well as any other anticancer agents, know in the art of cancer medicine, can be incorporated in the foam at therapeutically effective levels.
  • a preferred family of anticancer drugs, suitable for usage in the foam of the present formulation comprises antiestrogens, such as tamoxifen. Tamoxifen blocks the effects of the hormone estrogen in the body.
  • a safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the present invention, preferably from about 0.1% to about 10% (w/w), more preferably from about 1% to about 5% (w/w), of the composition.
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, ⁇ -hydroxy ⁇ .SJ. ⁇ -tetramethylchroman-a-carboxylic acid (commercially available under the tradename Trolox®), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g.
  • the foam of the present invention is suitable for delivering cell and tissue protecting and revitalizing anti-oxidants/radical scavengers.
  • Polyunsaturated fatty acids containing omega-3 and omega-6 fatty acids (e.g., linoleic and linolenic acid, gamma- linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial in the treatment of inflammation conditions.
  • omega-3 and omega-6 fatty acids e.g., linoleic and linolenic acid, gamma- linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial in the treatment of inflammation conditions.
  • GLA gamma- linoleic acid
  • EPA eicosapentaenoic acid
  • DHA doco
  • a tissue protective foam wherein the hydrophobic organic carrier comprises in full or in part, a solvent, selected from the group of emollients, silicone oil and oils, rich in unsaturated fatty acids, thus, affording a synergistic therapeutic effect of the anti-oxidants/radical scavenger agent and the vehicle components.
  • Active agents which are known in the art of pharmacology to treat mucosal irritations and inhibit inflammation, can be beneficially incorporated in the foam of the present invention.
  • Examples of such active agents include chamomile extract (matricaria recutitia), cucumber distillate (cucumis sativus), lavender water (lavendula angustifolia), rose water (rosa damascena), witch hazel (hamamelis virginiana), allantoin, bisabolol, rosehip oil, calendula oil, azulaene, menthol and camphor.
  • the foam particularly the silicone-oil based foam, as a lubricating foam. Typical examples are moisture protection foam and antifriction foam.
  • the foam can be used in its basic composition (without additional formulation aids and active ingredients), or with the addition of such additives.
  • the at least one active agent is selected from the group of solvent, surface active agent, foam adjuvant and polymeric agent.
  • Penetration enhancers are selected from the group of solvent, surface active agent, foam adjuvant and polymeric agent.
  • a penetration enhancer or permeation enhancer is an agent used to increase the permeability of tissue to a pharmacologically active agent to increase the rate at which the drug diffuses through the skin and enters the tissues and bloodstream.
  • a chemical penetration enhancer increases skin permeability by reversibly altering the physiochemical nature of the tissue to reduce its diffusional resistance.
  • a penetration enhancer is incorporated into the foam composition.
  • Examples of penetration enhancers include: polyols, such as propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, 1- menthol, dioxolane, ethylene glycol, other glycols, and glycerol; sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformanide, methyl dodecyl sulfoxide, dimethylacetamide; monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units); Azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1 ,3-dioxolane; esters, such as isopropyl myristate/palm
  • Lower alcohols such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol are less desirable penetration enhancers according to the present invention, due to their irritation properties.
  • Cyclodextrins are structurally related cyclic oligomaltoses which form a new group of therapeutic excipients.
  • Example 1 General Procedure for Preparing Foam Composition.
  • Aqueous Phase At least one polymeric agent and at least one surface-active agent are dissolved in water, with agitation. The solution is warmed to about 50 0 C to about 70°C. Water soluble therapeutic active ingredients and optional water soluble ingredients are added with agitation to the Aqueous Phase mixture.
  • Oil Phase At least one hydrophobic organic carrier is heated to same above temperature. Foam adjuvant agent is added to preheated hydrophobic organic carrier. Oil soluble therapeutic active agent or agents and optional oil soluble formulation ingredients are added with agitation to the Hydrophobic Phase mixture.
  • the warm Hydrophobic Phase is gradually poured into the warm Aqueous Phase, with agitation, followed by Ultraturax or Silverson homogenization.
  • Example 2 Emulsion Foam Carrier Composition for vaginal and rectal treatment
  • the liquefied or gas propellant can be added at a concentration of about 3% to about 25%.
  • the compositions use only non-ionic surface active agents, and the total amount of surface active agent, foam adjuvants and polymeric agent ranged from 1.4 to 2.1 % (w/w).
  • the foam of this example is useful as a carrier of active agents, as exemplified in examples below. It is also useful as lubricating foam, for various purposes.
  • the liquefied or gas propellant can be added at a concentration of about 3% to about 25%.
  • the foams of this example have a non-ionic surface active agent to ionic surface active agent ratio (w/w) of 20:1 and 14:1 for versions 1 and 2, respectively.
  • Total amounts of surface active agent foam adjuvant and polymeric agent is in the range of about 1.75 to about 3.5 % (w/w).
  • compositions are useful as carriers of active therapeutic active ingredients, as exemplified in examples below. It is also useful as lubricating foam, for various purposes.
  • Example 4 Antibacterial Foam Composition for vaginal vaginosis and other vaginal and rectal infections
  • the liquefied or gas propellant can be added at a concentration of about 3% to about 25%.
  • the foams of this example have a non-ionic surface active agent to ionic surface active agent ratio ranging from about 20:1 to about 6:1. In one version, no ionic surface active agent was present.
  • Example 5 Antifungal Foam Composition
  • the liquefied or gas propellant can be added at a concentration of about 3% to about 25%.
  • the foams of this example have a non-ionic surface active agent to ionic surface active agent ratio ranging from about 16:1 to about 6:1.
  • Total surface active agent, foam adjuvant and polymeric agent ranges from 2.05 to 3.5% (w/w). They are useful in the treatment of fungal and yeast infections.
  • the liquefied or gas propellant can be added at a concentration of about 3% to about 25%.
  • the foams of this example have a non-ionic surfactant to ionic surfactant ratio ranging from about 20:1 to about 14:1.
  • Total surface active agent, foam adjuvant and polymeric agent ranged from about 2% to about 3.5% (w/w).
  • Example 8 Compositions consisting of corticosteroids, antifungal and antiviral agents
  • the liquefied or gas propellant can be added at a concentration of about 3% to about 25%. Water content in these compositions was about 10%
  • Example 10 Animal model for drug administration and duration [0200] The composition of Example 4, Version 2 was prepared, with the addition of 0.2% methylene blue as coloring agent. A female sheep was administered intra-vaginally one dose of the foam (metered dose, 50 ⁇ L). The vagina and cervix were observed by colposcopy and recorded photographically. The insertion was very easy. Foam expanded effectively and vaginal cavity and cervix area were fully covered. Fifteen minutes after treatment, the vagina was swabbed. Colposcopy revealed that the entire vaginal cavity and cervix area were still covered by the blue pigment. There was no overflow of the foam and no dripping after administration. No signs of irritation were observed.
  • Example 11 The formulations of Example 11 are made stable with unexpectedly low surfactant concentration making them highly non irritating and of lower itching potential for conditions of damaged infected or diseased condition vaginal mucous.

Landscapes

  • Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un support de mousse cosmétique ou thérapeutique sans alcool comprenant de l'eau, un support organique hydrophobe, un agent adjuvant de moussage, un agent de surface actif et un agent gélifiant. Ce support de mousse cosmétique ou thérapeutique ne contient pas d'alcools aliphatiques, ce qui le rend non irritant et non déshydratant. Le support de mousse sans alcool est approprié pour y inclure des agents thérapeutiques et cosmétiques à la fois solubles dans l'eau et solubles dans l'huile.
PCT/IB2005/004164 2004-04-28 2005-04-28 Mousses pour cavites corporelles WO2006131784A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05857859A EP1768648A1 (fr) 2004-04-28 2005-04-28 Mousses pour cavites corporelles
CA002565754A CA2565754A1 (fr) 2004-04-28 2005-04-28 Mousses a cavites corporelles
IL173092A IL173092A (en) 2004-04-28 2006-01-12 Foam for body cavities

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56651304P 2004-04-28 2004-04-28
US60/566,513 2004-04-28

Publications (1)

Publication Number Publication Date
WO2006131784A1 true WO2006131784A1 (fr) 2006-12-14

Family

ID=35455796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/004164 WO2006131784A1 (fr) 2004-04-28 2005-04-28 Mousses pour cavites corporelles

Country Status (6)

Country Link
EP (1) EP1768648A1 (fr)
AU (1) AU2005204341A1 (fr)
CA (1) CA2565754A1 (fr)
IL (1) IL173092A (fr)
WO (1) WO2006131784A1 (fr)
ZA (1) ZA200507019B (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645803B2 (en) 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2011073995A3 (fr) * 2009-12-14 2011-08-11 Lincoln Pharmaceuticals Limited Liquide contenant de la progestérone à pulvériser dans le vagin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
WO2016048230A1 (fr) * 2014-09-25 2016-03-31 Lindal Åke Compositions formant une mousse et méthodes d'administration d'un agent actif dans une cavité corporelle
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11135166B2 (en) 2017-05-23 2021-10-05 Pharmiva Ab Foam-forming compositions for delivering an active to a body cavity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003115A1 (fr) * 1994-07-21 1996-02-08 Tillotts Pharma Ag Composition aqueuse moussante
WO2004037225A2 (fr) * 2002-10-25 2004-05-06 Foamix Ltd. Mousse cosmetique et pharmaceutique
WO2005011567A2 (fr) * 2003-08-04 2005-02-10 Foamix Ltd. Vehicule pour substance moussante contenant un agent gelifiant copolymere amphiphile
WO2005018530A2 (fr) * 2003-08-25 2005-03-03 Foamix Ltd. Mousse pharmaceutique de penetration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003115A1 (fr) * 1994-07-21 1996-02-08 Tillotts Pharma Ag Composition aqueuse moussante
US5972310A (en) * 1994-07-21 1999-10-26 Tillotts Pharma Ag Aqueous foamable composition
WO2004037225A2 (fr) * 2002-10-25 2004-05-06 Foamix Ltd. Mousse cosmetique et pharmaceutique
WO2005011567A2 (fr) * 2003-08-04 2005-02-10 Foamix Ltd. Vehicule pour substance moussante contenant un agent gelifiant copolymere amphiphile
WO2005018530A2 (fr) * 2003-08-25 2005-03-03 Foamix Ltd. Mousse pharmaceutique de penetration

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US7645803B2 (en) 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
WO2011073995A3 (fr) * 2009-12-14 2011-08-11 Lincoln Pharmaceuticals Limited Liquide contenant de la progestérone à pulvériser dans le vagin
RU2710019C2 (ru) * 2014-09-25 2019-12-24 Фармива АБ Пенообразующие композиции и способы доставки активного агента в полость тела
US9895311B2 (en) 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
WO2016048230A1 (fr) * 2014-09-25 2016-03-31 Lindal Åke Compositions formant une mousse et méthodes d'administration d'un agent actif dans une cavité corporelle
KR20170059000A (ko) * 2014-09-25 2017-05-29 파르미바 아베 활성제를 체강에 전달하기 위한 포말-형성 조성물 및 방법
KR102569954B1 (ko) 2014-09-25 2023-08-22 파르미바 아베 활성제를 체강에 전달하기 위한 포말-형성 조성물 및 방법
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US11135166B2 (en) 2017-05-23 2021-10-05 Pharmiva Ab Foam-forming compositions for delivering an active to a body cavity

Also Published As

Publication number Publication date
ZA200507019B (en) 2008-02-27
EP1768648A1 (fr) 2007-04-04
IL173092A (en) 2016-09-29
AU2005204341A1 (en) 2005-11-17
IL173092A0 (en) 2009-02-11
CA2565754A1 (fr) 2005-10-28

Similar Documents

Publication Publication Date Title
US9713643B2 (en) Foamable carriers
WO2006131784A1 (fr) Mousses pour cavites corporelles
US11103454B2 (en) Wax foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) Moisturizing foam containing lanolin
US9492412B2 (en) Penetrating pharmaceutical foam
AU2004266502B2 (en) Penetrating pharmaceutical foam
US20080206161A1 (en) Quiescent foamable compositions, steroids, kits and uses thereof
US20070292461A1 (en) Oleaginous pharmaceutical and cosmetic foam
US20060018937A1 (en) Steroid kit and foamable composition and uses thereof
EP1863447A2 (fr) Composition et kit d'immunomodulation non steroidiens et utilisations
AU2009205314A1 (en) Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2005204341

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200507019

Country of ref document: ZA

Ref document number: 2005/07019

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005204341

Country of ref document: AU

Date of ref document: 20050428

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2565754

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 3466/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005857859

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005857859

Country of ref document: EP